Medigene will present a poster at the 21th Association for Cancer Immunotherapy (CIMT) Annual Meeting taking place May 15-17, 2024, in Mainz, as well as at the Healthcare House Call Virtual Conference hosted by The Benchmark Company on May 21 and 22, 2024. 21st CIMT Annual Meeting Location: Rheingoldhalle Congress Center Mainz, GermanyDate: May 15 – 17 2024 Details on the poster presentation are as follows: Abstract and title: “Selection of superior KRAS G12V mutation-specific T cell receptors with unique characteristics for 3rd generation armored and enhanced T cell therapy”Authors: Julia Bittmann, Melanie Salvermoser, Dominik Alterauge, Anne-Wiebe Mohr, Doris Brechtefeld, Mario Catarinella, Petra U Prinz, Maja Buerdek, Kathrin Davari, Dolores J Schendel and Giulia LonginottiFinal abstract number: 3Date/time: Wednesday, May 15, 2024, poster session from 3:00 – 5:30pm (local time)Session: Cellular Therapy, Immunomonitoring, New Targets & New Leads The work to be presented will highlight preclinical data of the top-3 candidate T cell receptors (TCRs) targeting mutant Kirsten rat sarcoma (mKRAS) G12V including the discovery process to generate optimal affinity 3S (specific, sensitive and safe) TCRs. Further in vitro data will showcase beneficial effects when armoring 3S TCRs with the Company’s PD1-41BB costimulatory switch protein. The poster will be available on Medigene ́s website following the conference: Healthcare House Call Virtual Investor Conference hosted by The Benchmark CompanyDate: May 21-22, 2024 Members of Medigene’s management team will join a fireside chat and will be available for virtual meetings with registered investors. Please contact Dr. Fotini Vogiatzi at to schedule a meeting at the conference. — end of press release —